At the STAT Summit, Compass Pathways CEO Kabir Nath announced the company will 'go slow before we go fast' ahead of completing its rolling FDA submission for COMP360 synthetic psilocybin therapy in Q4 2026. Addressing treatment-resistant depression affecting 4 million Americans, Compass plans a cautious rollout under an expected FDA REMS protocol. However, experts like former NIMH Director Steven Hyman highlight key challenges, including functional trial unblinding.
COMP360 FDA submission and rollout strategy
- ▪Compass Pathways CEO Kabir Nath stated on October 14, 2026, that the company plans to complete its rolling FDA submission for COMP360 synthetic psilocybin treatment in the fourth quarter of 2026.
- ▪Compass Pathways is engaging commercial insurers and CMS regarding reimbursement mechanisms for clinical monitoring required during COMP360 psilocybin treatment sessions.
- ▪Compass Pathways CEO Kabir Nath stated at the STAT Summit that the company will go slow before it goes fast ahead of the COMP360 FDA submission to avoid early negative patient or provider experiences.
- ▪Compass Pathways expects COMP360 to be subject to an FDA risk evaluation and mitigation strategy (REMS) upon approval and is investing in provider training for drug administration.
COMP360 trial results and designations
- ▪COMP360 psilocybin treatment holds Breakthrough Therapy designation from the U.S. FDA and Innovative Licensing and Access Pathway designation in the UK for treatment-resistant depression.
- ▪In Compass Pathways Phase 3 trials, roughly 40% of treatment-resistant depression patients experienced a clinically meaningful response after receiving two doses of COMP360 three weeks apart.
- ▪Compass Pathways CEO Kabir Nath stated that COMP360 clinical trial session recordings revealed patients spent approximately 80% of session time in silence after the company deliberately separated psychotherapy from trial protocols.
Steven Hyman on psychedelic trial challenges
- ▪Former NIMH Director Steven Hyman warned at the STAT Summit that psychiatry lacks objective biomarkers to determine which patients will benefit from psychedelic treatments.
- ▪Former NIMH Director Steven Hyman questioned whether subjective psychedelic experiences are necessary for antidepressant efficacy, noting that non-hallucinogenic compounds could allow at-home prescriptions if proven effective.
- ▪Former NIMH Director Steven Hyman noted that functional unblinding remains a clinical trial challenge because patients recognize the subjective effects of psychedelic drugs, citing FDA's 2024 rejection of Lykos Therapeutics' MDMA therapy.
Burden of treatment-resistant depression
- ▪A survey commissioned by Compass Pathways revealed that nearly two in three caregivers report treatment-resistant depression impacts family health, with over half experiencing a major toll on their own mental health.
- ▪Treatment-resistant depression is estimated to affect approximately 4 million people in the U.S., with fewer than 5% receiving a treatment indicated for the condition.
- ▪A survey commissioned by Compass Pathways found that nearly 95% of individuals living with treatment-resistant depression describe themselves as functioning but struggling, surviving day-to-day, or barely getting by.
Treatment-resistant depression Awareness Day
- ▪Compass Pathways announced the establishment of the first Treatment-Resistant Depression Awareness Day in the U.S. on October 14, 2026.
- ▪The Treatment-Resistant Depression Awareness Day campaign is supported by the National Alliance on Mental Illness, Mental Health America, and the Depression and Bipolar Support Alliance.
Story comments
Loading comments…